CANADIAN ASSOCIATION OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)

What CANADIAN ASSOCIATION OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) does

The Canadian Association of Paroxysmal Nocturnal Hemoglobinuria (PNHCA) is a federally-incorporated Canadian not-for-profit founded in 2009 by PNH patient Barry Katsof and headquartered at 1321 Sherbrooke St. West, Suite A-41, Montreal, Quebec. The organization's stated mission is to empower people with PNH to live their best lives through advocacy, education, and peer support, and it is the only national patient association in Canada dedicated specifically to PNH — an ultra-rare blood disorder affecting approximately 200 Canadians at a global incidence of 0.5–1.5 per million.

PNHCA operates a content-and-community platform centered on its website (pnhca.org), launched in a refreshed form on December 1, 2025. The product surface includes the Better Living with PNH Guide (a 10-week bi-weekly email curriculum with named wellness experts), a quarterly newsletter, a Find a PNH Specialist directory spanning seven Canadian provinces, downloadable Patient Exploration Guides (Doctor Discussion Guide, Coverage Options Guide), and a Patient Support Programs Directory listing manufacturer programs for all five PNH therapies approved in Canada. The underlying technology stack is a SiteGround-hosted website with Polylang for bilingual delivery, MailChimp for email, Google Analytics for traffic analysis, and Facebook Custom Audience for advertising; the privacy policy asserts compliance with GDPR, PIPEDA, CCPA, and UK GDPR.

The business model is mission-driven and non-commercial: all patient-facing services are free, the organization explicitly states it 'do[es] not charge anything, and we do not expect to,' and revenue (not publicly disclosed) is funded primarily through pharmaceutical manufacturer sponsorships. Four sponsors — Alexion, Novartis, Roche, and Sobi — are acknowledged on the website, each of which markets an approved PNH therapy in Canada. Customer segments are split horizontally across PNH patients (primary), caregivers and family members, and healthcare professionals; the organization additionally maintains referral relationships with the Aplastic Anemia & Myelodysplasia Association of Canada (AAMAC), the Canadian Organization for Rare Disorders (CORD), Le Regroupement Québécois des Maladies Orphelines (RQMO), and the Canadian PNH Network.

Name

CANADIAN ASSOCIATION OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)

Legal name

Canadian Association of Paroxysmal Nocturnal Hemoglobinuria

Website

https://pnhca.org

Company type

Private

Founded year

2009

Operating status

Operating

Short description

PNHCA is a Canadian non-profit founded in 2009 that provides free advocacy, education, and peer-support services to the approximately 200 Canadians living with paroxysmal nocturnal hemoglobinuria, their caregivers, and treating clinicians.

Ownership category

akta.pro rank

Headquarters

HQ city

Montreal

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Distribution channels2 records

Marketing channels5 records

Core offering

The Canadian Association of Paroxysmal Nocturnal Hemoglobinuria (PNHCA) is a federally-incorporated Canadian not-for-profit that delivers advocacy, education, and peer-support services to people living with PNH and their families across Canada. Its offerings center on free digital resources—a 5-week Better Living with PNH wellness program, a quarterly newsletter, downloadable exploration guides (Doctor Discussion Guide, Coverage Options Guide), a province-wide PNH specialist locator, and patient stories—sustained through pharmaceutical sponsorships.

Product overview

The Canadian Association of PNH Patients (PNHCA) operates a comprehensive patient advocacy platform centered on its main website (pnhca.org), which serves as an educational hub for PNH patients and caregivers. The core offering includes the main website platform providing access to disease information, patient stories, and healthcare resources. Supporting this are digital products including the Better Living with PNH Guide (a 5-week wellness program), the quarterly PNHCA Newsletter, and downloadable Patient Exploration Guides (Doctor Discussion Guide, Coverage Options Guide). Additional tools include the Find a PNH Specialist locator for connecting patients with Canadian specialists, and a Patient Support Programs Directory listing pharmaceutical manufacturer support programs for PNH medications.

Differentiator

Problem solved

Functional benefit

Products and services

• Better Living with PNH Guide A 5-week curated wellness program covering fitness, nutrition, yoga, and patient stories, delivered bi-weekly to subscribers via email. Designed for people living with PNH to help them manage lifestyle alongside their condition.
• PNHCA Newsletter A quarterly email newsletter providing expert insights, latest PNH news, useful tips, and inspiring community stories. Subscribed to via the website and delivered through MailChimp.
• Doctor Discussion Guide A downloadable PDF guide helping patients track symptoms, record reminders, and prepare questions for appointments with their PNH specialists. Targeted at people living with PNH preparing for medical consultations.
• Coverage Options Guide A downloadable guide providing information on provincial medication-coverage programs for PNH treatments SOLIRIS, ULTOMIRIS, EMPAVELI, VOYDEYA, and FABHALTA across Canada. Aimed at PNH patients navigating provincial reimbursement.
• Find a PNH Specialist Tool An interactive online directory allowing patients to search for PNH specialists by province or territory across Canada, with clinic information and contact details for British Columbia, Alberta, Manitoba, Ontario, Quebec, Nova Scotia, Newfoundland and Labrador.

Quantifiable outcome

• Five PNH therapies now approved in Canada with more in development
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• AlexioncoreGTM or Marketing Partner · 1 December 2025Pharmaceutical company sponsor of PNHCA website development. One of four pharmaceutical sponsors acknowledged for supporting the organization's mission to serve the PNH community.
• NovartiscoreGTM or Marketing Partner · 1 December 2025Pharmaceutical company sponsor of PNHCA website development. Supports the organization's patient education and advocacy efforts.
• RochecoreGTM or Marketing Partner · 1 December 2025Pharmaceutical company sponsor of PNHCA website development. Supports patient access to PNH information and resources.
• SobicoreGTM or Marketing Partner · 1 December 2025Pharmaceutical company (Swedish Orphan Biovitrum) sponsor of PNHCA website development. Supports FABHALTA patient assistance programs including FABHALTA Assist.
• Aplastic Anemia & Myelodysplasia Association of Canada (AAMAC)minorOthersCanadian patient organization serving related blood disorders. Listed as a resource for patients to connect with additional support organizations.
• Canadian Organization for Rare Disorders (CORD)minorOthersNational advocacy organization for rare disorders in Canada. Listed as a resource connecting PNH patients with broader rare disease community.
• Le Regroupement Québécois des Maladies Orphelines (RQMO)minorOthersQuebec-based rare disease organization. Resource for French-speaking Quebec patients seeking local disease support.
• Canadian PNH NetworkminorOthersHealthcare professional network focused on PNH. Listed as a resource for connecting patients with PNH-specialized medical professionals.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Canadian Organization for Rare Disorders (CORD): CORD is Canada's national network for rare disease patient organizations. It is a direct peer of PNHCA in that it aggregates and represents many small, disease-specific Canadian patient associations like PNHCA, and is already a listed partner.
• Aplastic Anemia & Myelodysplasia Association of Canada (AAMAC): AAMAC is a Canadian patient advocacy organization for related rare blood disorders (aplastic anemia and MDS). It is directly comparable to PNHCA in mission, scale, structure, and Canadian geography, and is already a listed partner resource.
• AAMDS International Foundation (AAMDSIF): AAMDSIF is a US-based patient advocacy organization for aplastic anemia, MDS, and PNH. It is a direct peer to PNHCA, covering PNH patients in a different geography with similar mission, programs, and pharma sponsorship model.
• Canadian Hemochromatosis Society: Canadian Hemochromatosis Society is a Canadian patient advocacy organization for another rare blood disorder. It is a direct peer to PNHCA in scale, mission, and Canadian rare-disease patient-association model.
• Canadian Sickle Cell Association: A Canadian patient advocacy organization for sickle cell disease. Comparable to PNHCA as a Canadian rare blood disease patient association with similar resources, advocacy focus, and pharma sponsorship model.
• Le Regroupement Québécois des Maladies Orphelines (RQMO): RQMO is a Quebec-based rare disease coalition. It is a direct peer of PNHCA in mission and Canadian (Quebec) geography, and is already a listed partner resource.
• Pulmonary Hypertension Association of Canada: A Canadian patient advocacy organization for pulmonary hypertension, another rare disease. Comparable to PNHCA in mission, structure, pharma sponsorship, and Canadian patient-association model.
• PNH Global Alliance: An international alliance of PNH patient organizations. PNHCA is a likely member; this is a direct peer in the same rare disease space with global scope.

Broad incumbents

• National Organization for Rare Disorders (NORD): NORD is the largest US rare disease umbrella advocacy organization. It is a broad incumbent peer to PNHCA, providing rare disease patients (including PNH) with advocacy, education, and research support across many conditions.

Emerging players

• Blood Disorders Alliance Canada: A Canadian coalition focused on blood disorders. Comparable to PNHCA as an emerging umbrella organization in the same advocacy space, with potential overlap in patient communities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/PNHCanada

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CANADIAN ASSOCIATION OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)